1Matthews R.Autoimmune diseases.The B cell slayer.Science,2007,318:1232-1233.
2Shlomchik M J,Madaio M P,Ni D,et al.The role of B cells in lpr/lpr-induced autoimmunity.J Exp Med,1994,180:1295-1306.
3Chan O T,Hannum L G,Haberman A M,et al.A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus.J Exp Med,1999,189:1639-1648.
4Tedder T F,Engel P.CD20:a regulator of cell-cycle progression of B lymphocytes,Immunol Today,1994,15:450-454.
5Edwards J C,Szczepanski L,Szechinski J,et al.Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.N Engl J Med,2004,350:2572-2581.
6Kavanaugh A F.B cell targeted therapies:safety considerations.J Rheumatol Suppl,2006,77:18-23.
7Gottenberg J E,Guillevin L,Lambotte O,et al.Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.Ann Rheum Dis,2005,64:913-920.
8Seror R,Sordet C,Guillevin L,et al.Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren ' s syndrome.Ann Rheum Dis,2007,66:351-357.
9Pijpe J,van Imhoff G W,Vissink A,et al.Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma.Ann Rheum Dis,2005,64:958-960.
10Visvanathan S,Marini J C,Smolen J S,et al.Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.J Rheumatol,2007,34:1465-1474.
二级参考文献20
1Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982, 25: 1271-1277.
2Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet, 1997, 24 : 1-8.
3D' Alfonso S, Giordano M, Mellai M, et al. Association tests with systemic lupus erythematosus (SLE) of IL10 markers indicate a direct involvement of a CA repeat in the 5' regulatory region. Genes Immun, 2002, 3:454-463.
4Kelly JA, Moser KL, Harley JB. The genetics of systemic lupus erythematosus: putting the pieces together. Genes Immun,2002,3 (suppl 1) :S71-S85.
5Mosmann TR. Properties and functions of interleukin-10. Adv Immunol , 1994,56 : 1-26.
6Ding L, Linsley PS, Huang LY, et al. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the upregulation of B7 expression. J Immunol, 1993,151 : 1224-1234.
7Rousset F, Garcia E, Defrance T, et al. Interleukin-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA, 1992,89:1890-1893.
8Ishida H, Muchamuel T,Sakaguchi S, et al. Continuous administration of anti-interleukin-10 antibodies delays the onset of autoimmunity in NZB/W F1 mice. J Exp Med, 1994, 179: 305-310.
9Laski JK, Leszczynski P, Kelemen J, et al. Cyctokine concentration in serum of lupus erythematosus patients:the effect on acute phase response. J Med, 1997,28:99-107.
10Park YB, Lee SK, Kim DS, et al. Elevated interleukine-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol, 1998,16:283-288.
